12:00 AM
Sep 20, 2010
 |  BC Week In Review  |  Company News  |  Deals

Covella Pharmaceuticals Inc., Biogen Idec, Santarus deal

Santarus acquired Covella for $648,000 in cash and stock and will assume about $1.2 million of Covella liabilities and transaction expenses. Covella shareholders are eligible for milestones, plus royalties on sales of products resulting from Covella's anti-

Read the full 170 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >